

REMARKS

Claims 1-31 are pending in this application. In the Office Action, the Examiner has set forth a restriction requirement contending that the application contains claims directed to the following patentably distinct inventions:

Group I: Claims 1-11, 28-31, drawn to method of treating neoplastic, fibroblastic and/or immunosuppressive using a uracil based medicament, classified in class 514, subclass 256; and,

Group II: Claims 12-27, drawn to an ocular iontophoretic device, classified in class 604, subclass 892.1.


In response to the Examiner's request, the Applicant hereby elects the claims of Group II, i.e., Claims 12-27, without traverse and cancels Claims 1-11 and 28-31. As such, Claims 12-27 are pending in this application. The Applicant notes that the amendment to the claims does not require an amendment to the inventorship of this case.

The present application—as amended—is respectfully submitted to be in condition for prosecution on the merits.

Applicant believes that no fees are required with this communication, however if any additional fees are required, they may be paid out of our Deposit Account No. 50-0545.

Respectfully submitted,


Dated: July 17, 2007



Joseph M. Kinsella Jr.
One of Attorneys for Applicant

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on July 17, 2007.



Yolanda Solis